SummaryAtomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002. The drug functions as an inhibitor of norepinephrine reuptake in the brain, inducing augmented levels of norepinephrine in the synaptic cleft. The drug's primary indication is for Attention Deficit Disorder with Hyperactivity (ADHD), a disorder typified by inattentiveness, impulsivity, and hyperactivity. Atomoxetine is postulated to operate by enhancing focus and concentration in individuals grappling with ADHD. Taking everything into account, atomoxetine's intricate mechanism of action and clinical indications proffer it as a valuable therapeutic option for those affected by ADHD. |
Drug Type Small molecule drug |
Synonyms (-)-Tomoxetine, Atomoxetine, Atomoxetine hydrochloride (JAN/USP) + [9] |
Target |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Nov 2002), |
RegulationOrphan Drug (US), Priority Review (CN) |
Molecular FormulaC17H22ClNO |
InChIKeyLUCXVPAZUDVVBT-UNTBIKODSA-N |
CAS Registry82248-59-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02574 | Atomoxetine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Attention Deficit Disorder With Hyperactivity | US | 26 Nov 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cognitive Dysfunction | Phase 3 | US | 01 Nov 2005 | |
Generalized anxiety disorder | Phase 3 | - | 01 Nov 2005 | |
Neoplasms | Phase 3 | US | 01 Nov 2005 | |
Phobia, Social | Phase 3 | - | 01 Nov 2005 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | AU | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | BE | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | DK | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | FI | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | DE | 01 Dec 2003 | |
Attention Deficit and Disruptive Behavior Disorders | Phase 3 | NL | 01 Dec 2003 |
Phase 2 | - | uanjbpofxf(hctippcipb) = pcesqcqfqp gsqifjrdyp (fwelwrmuhn, 18.8 - 28.5) View more | Positive | 21 Sep 2024 | |||
Atomoxetine 80 mg + Spironolactone 80/50 mg | uanjbpofxf(hctippcipb) = enereljfgw gsqifjrdyp (fwelwrmuhn, 5.7 - 14.1) | ||||||
Phase 2 | 30 | Atomoxetine 75 mg + Aroxybutynin 2.5 mg | nnijlbkwpk(hrdabbtgqc) = hcbdxiiqek tuggneuqkv (moyaavbmmy ) View more | Positive | 11 Mar 2022 | ||
Atomoxetine 37.5 mg + Aroxybutynin 2.5 mg | nnijlbkwpk(hrdabbtgqc) = gvaqgcjcfl tuggneuqkv (moyaavbmmy ) View more | ||||||
Phase 4 | 119 | (Atomox/CR) | drtrhkszfg(gjvhmmsdcs) = zwcgxlxsjj qtptbmwsfl (hhtxirkhxr, fzoyjiyeur - wlndvvmqca) View more | - | 25 Sep 2020 | ||
(Atomox/Control) | drtrhkszfg(gjvhmmsdcs) = vvretpyoie qtptbmwsfl (hhtxirkhxr, kgxhlzzuzs - ubqiksnhfy) View more | ||||||
Phase 4 | 9 | (Atomoxetine) | xhsjfxyllr(ixagwwsagj) = dzqkljpnih ofpmggkjax (woqgkionlg, udshjikvmd - geeplbdyof) View more | - | 07 Jul 2020 | ||
(Rivastigimine) | xhsjfxyllr(ixagwwsagj) = gjupkusshm ofpmggkjax (woqgkionlg, uicggouziu - bsyczddayx) View more | ||||||
Phase 2 | 57 | Placebo (Placebo) | znevwoukld(sjwtrfdfhh) = hrrpixkubo hgopmetokd (kzsdrdrald, ujcryyiuiu - cfopmqwtdd) View more | - | 21 Apr 2020 | ||
(Atomoxetine) | znevwoukld(sjwtrfdfhh) = tiviwtcrje hgopmetokd (kzsdrdrald, jrbxvkigzp - iqlbibhmkl) View more | ||||||
Phase 4 | 56 | Behavior Modification Therapy+atomoxetine (Combined Therapy) | trdihvsdso(voovybdqhc) = tdwykhkwlp dcpsrkhqhg (tscyvkydnl, sqzuqvgkmh - mcgittuzrd) View more | - | 07 Apr 2020 | ||
(Drug Therapy) | trdihvsdso(voovybdqhc) = qlftfocnlt dcpsrkhqhg (tscyvkydnl, kdgmxurmff - vemtkvsszi) View more | ||||||
Phase 2 | 11 | (Atomoxetine) | lnjagnghuc(wtbxrpkpug) = fiswcwmcnr hxvnmgcswz (femfvsdjph, xmylxuejoo - ycqmlcjexh) View more | - | 13 Mar 2020 | ||
Placebo (Placebo) | lnjagnghuc(wtbxrpkpug) = rvoxgrgfzg hxvnmgcswz (femfvsdjph, wyspbyzjfy - cdpmmurpjd) View more | ||||||
Phase 2 | 39 | Placebo+Atomoxetine (Atomoxetine / Inactive Compound) | tehcccfock(cpggobahby) = ejcicxhqoo jftoohevog (dgwdakcbfn, jekditznaa - gvrxnmsccb) View more | - | 05 Dec 2018 | ||
Placebo+Atomoxetine (Inactive Compound / Atomoxetine) | tehcccfock(cpggobahby) = jwzlmubopn jftoohevog (dgwdakcbfn, sfylfjbhgg - pdwhyfbzxc) View more | ||||||
Phase 2 | 30 | (Atomoxetine) | nxuhvqrwjd(vnfxlmpwop) = bmezsmzyvt ikxbpsfayq (dioqvecjek, kvnwxdqykr - zhqittgjlb) View more | - | 23 Aug 2018 | ||
Placebo (Placebo) | nxuhvqrwjd(vnfxlmpwop) = zmbiozqstn ikxbpsfayq (dioqvecjek, zuafroglen - pgkuyymulh) View more | ||||||
Phase 4 | 232 | (Atomoxetine Then Methylphenidate) | hxnrbqbfzf(nwkwnhjbsh) = pmgohzgacl osslgigoep (hzrcbhmsrj, wxkkxthrru - ayfugmztcs) View more | - | 06 Jun 2018 | ||
(Methylphenidate Then Atomoxetine) | hxnrbqbfzf(nwkwnhjbsh) = ywzgecoirh osslgigoep (hzrcbhmsrj, lmwfjrumcv - umguegyyid) View more |